Top 10 Sales KPIs for Pharmacy Benefit Manager (PBM) in 2027

1PBM Scripts Dispensed KPI

Scripts Dispensed (30-day adjusted) ranks first because it is the base unit every other PBM metric divides against. CVS Caremark processed roughly 1.9 billion adjusted claims in 2025, about 31% share, while the Big-3 together adjudicate near 80% of U.S. claims. A rebate-retention percentage or formulary-adherence rate is meaningless without the claim count it applies to.

This KPI is for PBM finance and adjudication teams who must reconcile RxClaim counts against finance ledgers and rebate aggregator feeds. It trades away nothing analytically but demands clean 90-day-to-30-day conversion logic. Compared to Rebate Retention below it, Scripts Dispensed is volume while Rebate Retention is margin — both are required before any client-level P&L closes.

2PBM Rebate Retention KPI

Rebate Retention versus Pass-Through % ranks second because it is the margin line being legally dismantled. The Consolidated Appropriations Act of 2026 mandates 100% rebate pass-through to ERISA group plans, and the FTC's February 2026 Express Scripts settlement forces cost-plus reimbursement. Legacy retention assumptions now produce 200-400 basis-point EBITDA misses at annual true-up.

This KPI serves PBM pricing and actuarial teams rebuilding 2027 P&Ls around pass-through plus PMPM fees. It trades away the hidden margin that historically subsidized near-zero admin fees. Compared to Scripts Dispensed above it, Rebate Retention is the profit-per-claim counterpart to raw volume, and the two must reconcile before client reporting.

3PBM Generic Dispensing Rate KPI

Generic Dispensing Rate ranks third because a single percentage point of GDR improvement cuts a plan's gross drug spend roughly 5%. Industry averages sit in the high 80s, with best-in-class PBMs running 90% or higher, and GDR is contractually guaranteed on most large-employer deals. It is the most closely monitored operational metric in PBM contracts.

This KPI is for formulary and clinical teams managing prior-authorization workflows and non-preferred fill leakage. It trades away some brand-manufacturer rebate volume in exchange for lower net plan cost. Compared to Rebate Retention above it, GDR is a cost lever while retention is a revenue lever, and the two move in opposite directions on brand-heavy formularies.

4PBM Specialty Pharmacy Mix KPI

Specialty Pharmacy Mix ranks fourth because specialty scripts are under 2% of volume but drove roughly $293.4 billion in dispensing revenue in 2025, up 9.6% year over year, and exceed half of total plan drug spend. The Big-3 PBMs own the three largest specialty pharmacies, capturing close to two-thirds of pharmacy-dispensed specialty revenue.

This KPI is for PBM strategy and compliance teams balancing margin capture against ERISA fiduciary-breach risk from aggressive steerage. It trades away some plan-sponsor goodwill when steerage is pushed too hard. Compared to Generic Dispensing Rate above it, Specialty Mix is the margin engine while GDR is the cost engine, and specialty concentration is the bigger regulatory exposure.

5PBM Client Retention KPI

Client Retention ranks fifth because best-in-class PBMs hold 95%+ annual retention on employer and health-plan books, with industry average in the 90-93% range. A single large non-renewal moves billions of scripts in one cycle, as Anthem's 2019 exit from Express Scripts and CalPERS's 2026 exit from OptumRx demonstrated. Anything below 90% on a meaningful book triggers root-cause review.

This KPI is for PBM account management and executive teams owning the renewal pipeline and quarterly business reviews. It trades away short-term margin when clients demand transparent pricing to renew. Compared to Specialty Pharmacy Mix above it, Client Retention is the lagging outcome while specialty mix is a leading driver of whether the client stays.

6PBM PMPM Admin Fee KPI

PMPM Admin Fee ranks sixth because it is undergoing the fastest structural change of any PBM metric. Legacy fees ran $0.50-$2.00 per member per month, subsidized by rebate retention and spread. Under the 2026 CAA and FTC settlement, replacement fees are migrating to a $5-$15 PMPM range, a five-to-ten-fold increase in the visible line item.

This KPI is for PBM pricing teams running dual books in 2027, with legacy contracts in run-off alongside new pass-through-plus-PMPM contracts. It trades away the pricing flexibility that hidden rebate margin once provided. Compared to Client Retention above it, PMPM Admin Fee is the new visible revenue line that determines whether retention is even profitable.

7PBM Formulary Adherence KPI

Formulary Adherence ranks seventh because above 85% is considered healthy while below 75% signals value leakage through prior-authorization failures and non-preferred fills. It feeds directly into the rebate calculation, so it must be locked before rebate figures are published to clients. Adherence drives both plan cost and manufacturer rebate eligibility.

This KPI is for PBM clinical and client-service teams managing PA turnaround and formulary exception workflows. It trades away member convenience when tighter adherence rules are enforced. Compared to PMPM Admin Fee above it, Formulary Adherence is an operational input while PMPM is a financial output, and adherence failures erode the fee's value proposition.

8PBM Mail-Order Penetration KPI

Mail-Order Penetration ranks eighth because mail dispensing carries margins roughly 200-400 basis points above retail-network spread on maintenance medications. PBMs target 25-35% mail penetration on maintenance categories to improve blended profitability. It is one of the few channel metrics a PBM can move through member engagement rather than contract terms.

This KPI is for PBM channel strategy and member-engagement teams driving auto-refill and 90-day conversion programs. It trades away some member choice for higher per-script margin. Compared to Formulary Adherence above it, Mail-Order Penetration is a margin lever while adherence is a cost lever, and the two together shape blended per-claim profitability.

9PBM 340B Contract-Pharmacy Revenue KPI

340B Contract-Pharmacy Revenue ranks ninth because it is the most volatile line on the PBM scorecard. Manufacturer restrictions imposed by Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca, and Boehringer Ingelheim have been cutting covered-entity revenue at safety-net providers since 2023, with pressure expected to continue through 2027. It remains the fastest-growing PBM-adjacent revenue line.

This KPI is for PBM specialty contracting and regulatory teams managing covered-entity relationships and manufacturer policy shifts. It trades away revenue predictability for exposure to manufacturer-imposed restrictions. Compared to Mail-Order Penetration above it, 340B is a smaller but more volatile line, and it is the only KPI on this list driven primarily by external legal risk.

10PBM Spread Pricing KPI

Spread Pricing ranks tenth because it is a legacy metric being eliminated rather than optimized. The FTC's February 2026 Express Scripts settlement forces cost-plus reimbursement and ends spread pricing on that book, with CVS Caremark's TrueCost and OptumRx's Cost Clarity rolling out fully by 2028. Tracking spread in 2027 is a run-off exercise, not a growth lever.

This KPI is for PBM finance and compliance teams managing legacy contract wind-downs and cost-plus transitions. It trades away the invisible margin pool that once subsidized low PMPM fees. Compared to 340B Contract-Pharmacy Revenue above it, Spread Pricing is a shrinking revenue pool while 340B is a growing but volatile one, and both now sit under active regulatory scrutiny.

How we ranked these

This ranking measured nine PBM sales KPIs against three weighted criteria: claim-volume leverage (30%), margin durability under 2026 pass-through reform (40%), and client-book retention impact (30%). Each metric was scored on whether it moves gross margin, survives the shift from rebate retention to cost-plus PMPM pricing, and predicts renewal risk. Scripts Dispensed anchors everything; specialty mix and rebate retention carried the heaviest margin weight.

Deliberately ignored: brand-awareness or marketing-funnel metrics, since PBM contracts are won through consultant-led RFPs, not inbound demand. Also excluded were generic operational uptime stats and member-satisfaction scores, which rarely appear in a CFO's renewal model. Vanity volume without margin context was down-weighted, because a PBM can grow scripts while destroying economics under spread-pricing bans.

What to look for

When choosing between these KPIs, weight by margin durability first, not historical familiarity. Rebate Retention and Specialty Mix tell you whether the book survives 2027 reform; Scripts Dispensed and GDR tell you whether the underlying engine is healthy. A PBM with strong volume but weak pass-through readiness is a melting ice cube, no matter how good the retention number looks.

The mistake most buyers make is benchmarking against 2024–2025 industry averages that still embed rebate-subsidized economics. A 92% retention rate or $1.50 PMPM fee looks fine against legacy peers but is mispriced against cost-plus competitors. Rebuild every benchmark on post-settlement assumptions, then compare — otherwise you are buying yesterday's scorecard at tomorrow's price.

Related questions

How is a 30-day adjusted script calculated?

It converts every fill to a common 30-day-supply unit, so a 90-day mail-order fill counts as three scripts. This standardizes volume comparisons across retail, mail, and specialty channels for both revenue and rebate calculations, and it is the base unit every other PBM metric divides against.

What triggered the shift away from rebate retention?

The Consolidated Appropriations Act of 2026 mandated 100% rebate pass-through to ERISA group plans, and the FTC's February 2026 settlement with Express Scripts separately forced cost-plus reimbursement and ended spread pricing on that PBM's book, collapsing the legacy hidden-margin model.

Why do PBMs want higher mail-order penetration?

Mail-order dispensing carries margins roughly 200–400 basis points above retail-network spread on maintenance medications, so PBMs target 25–35% mail penetration on those categories. Higher penetration improves blended profitability and gives the PBM more control over adherence and refill timing.

What is 340B contract-pharmacy revenue?

It is fee revenue earned administering discounted drug programs for covered entities like safety-net hospitals and community health centers. It is currently the fastest-growing PBM-adjacent revenue line but also the most exposed to manufacturer-imposed restrictions from Sanofi, Lilly, Novo Nordisk, and others.

How does PMPM admin fee differ from rebate retention?

PMPM admin fee is the visible per-member monthly charge a plan sponsor pays; rebate retention is the hidden share of manufacturer rebates the PBM keeps. Under 2027 cost-plus reform, profit migrates from the second to the first, pushing fees from $0.50–$2.00 toward $5–$15.

What is a healthy client retention rate for a PBM?

Best-in-class PBMs hold 95%+ annual retention on employer and health-plan books, with the industry average in the 90–93% range. Anything below 90% on a meaningful book should trigger root-cause review, since one large non-renewal can move billions of scripts.

Why does specialty pharmacy mix drive PBM margin?

Specialty scripts are under 2% of volume but over half of total plan drug spend, and the three largest specialty pharmacies are all PBM-owned, capturing close to two-thirds of pharmacy-dispensed specialty revenue. Mix is the single biggest lever on gross margin.

What formulary adherence rate signals value leakage?

Above 85% is considered healthy; below 75% signals leakage through prior-authorization failures and non-preferred fills. Adherence feeds directly into the rebate calculation, so it must be locked before rebate figures are published to clients or consultants.

FAQ

What is a 30-day adjusted script and why does it matter?

A 30-day adjusted script converts all prescription fills to a common 30-day supply unit, so a 90-day mail-order fill counts as three scripts. This standardizes volume across channels and is the primary driver of per-claim revenue in both rebate and cost-plus models.

How does rebate retention differ from pass-through in 2027?

Rebate retention is the share of manufacturer rebates the PBM keeps as profit; pass-through means 100% of rebates go to the plan sponsor. Under the 2026 reforms, most large PBMs are shifting profit from hidden rebate spreads to transparent PMPM admin fees instead.

What is a healthy generic dispensing rate for a PBM?

Industry benchmarks typically run in the high 80s to low 90s percent. A higher GDR lowers plan drug costs and reduces exposure to brand-price inflation, making it one of the most closely contractually monitored metrics in the industry.

Why is specialty pharmacy mix such a critical metric?

Specialty drugs are under 2% of prescription volume but over half of total plan drug spend, and dispensing revenue is heavily concentrated among the three largest, PBM-owned specialty pharmacies. Specialty mix is the single biggest lever on gross margin in the entire model.

What drives client retention in the PBM industry?

Annual retention among employer and health-plan clients typically runs 90–95%. The main drivers are transparent pricing, formulary flexibility, demonstrated net cost savings versus competitors, and service-level performance on claims and prior authorization.

How are PMPM admin fees changing under cost-plus models?

Legacy PMPM fees ran $0.50–$2.00, subsidized by rebate retention. Under 2027 cost-plus structures, fees are migrating to roughly $5–$15 per member per month, reflecting the true administrative and clinical cost of running the benefit transparently.

Which PBM KPI is most exposed to regulatory change?

Rebate Retention versus Pass-Through % is the most exposed, because the 2026 CAA and FTC settlement directly prohibit the legacy retention structure. Any 2027 model still built on rebate retention assumptions risks a 200–400 basis-point EBITDA miss at true-up.

How often should PBM KPIs be reviewed?

Operational metrics like claims processed and prior-auth turnaround need daily visibility. Formulary and channel metrics fit a weekly review. Margin and PMPM metrics belong monthly, and retention, regulatory exposure, and 340B pipeline belong in the quarterly board cycle.

What is the biggest mistake PBM teams make with these KPIs?

Rebate-retention denial: modeling 2027 and 2028 finances on legacy rebate assumptions that the CAA and FTC consent order prohibit. The gap surfaces only at the annual true-up, by which point it cannot be recovered mid-contract.

How does 340B contract-pharmacy revenue affect PBM forecasting?

It is the most volatile line on the scorecard. Manufacturer restrictions imposed since 2023 by Sanofi, Lilly, Novo Nordisk, AstraZeneca, and Boehringer Ingelheim keep cutting covered-entity revenue, so 340B forecasts should be scenario-based rather than single-point.

Sources

• https://www.drugchannels.net
• https://www.pbmi.com
• https://www.ftc.gov
• https://www.cvshealth.com/investors
• https://www.cigna.com/investors
• https://www.unitedhealthgroup.com/investors
• https://www.kff.org
• https://www.ncpa.org
• https://www.ajmc.com
• https://www.frierlevitt.com

Related on PULSE

• More sales kpis for pharmacy benefit manager (pbm) rankings and buying guides
• PULSE Tools and calculators
• Everything on PULSE RevOps